Aligos Completes Enrollment in Phase 2 HBV Trial Ahead of Schedule — Aligos Therapeutics, Inc.

Event summary

Aligos Therapeutics completed enrollment in its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic HBV, ahead of the planned second interim analysis.
The trial enrolled 131 HBeAg+ participants (Part 1a) and 114 HBeAg- participants (Part 2a).
Topline safety and efficacy data are expected in late Q3 2027.

The big picture

Aligos' accelerated enrollment in the B-SUPREME study underscores the unmet need for better chronic HBV therapies. With 240 million patients globally and rising mortality from HBV-related liver cancer, pevifoscorvir sodium's potential as a best-in-class capsid assembly modulator could reshape treatment paradigms if Phase 2 results validate its efficacy and safety profile.

What we're watching

Regulatory Pathway: Whether pevifoscorvir sodium's chronic suppressive pathway, acknowledged by FDA, EMA, and NMPA, will streamline future approvals.
Clinical Efficacy: The magnitude of HBV DNA reduction and safety profile demonstrated in the topline data due in late 2027.
Competitive Positioning: How Aligos positions pevifoscorvir sodium against existing HBV treatments like tenofovir disoproxil fumarate.